Loading...
XHKG
3933
Market cap3.49bUSD
Jul 16, Last price  
15.08HKD
1D
2.86%
1Q
18.93%
Jan 2017
185.61%
IPO
364.00%
Name

United Laboratories International Holdings Ltd

Chart & Performance

D1W1MN
No data to show
P/E
9.42
P/S
1.82
EPS
1.46
Div Yield, %
2.73%
Shrs. gr., 5y
2.07%
Rev. gr., 5y
10.39%
Revenues
13.76b
+0.14%
2,086,097,2162,430,926,9343,307,047,9564,088,081,9545,541,863,1925,183,778,6825,653,764,4645,971,793,4366,422,409,9616,445,983,2436,077,944,0006,826,645,0007,510,586,0008,392,600,0008,772,488,0009,703,438,00011,334,262,00013,739,879,00013,758,937,000
Net income
2.66b
-1.54%
174,307,439478,199,761378,765,722476,713,112830,200,94584,391,079130,422,79237,536,441544,615,84492,411,554-272,363,00081,758,000682,928,000641,764,000702,989,000988,098,0001,581,094,0002,701,350,0002,659,704,000
CFO
0k
-100.00%
286,241,898337,572,611610,511,854653,134,902569,463,560411,542,580475,737,1771,155,133,1161,400,007,7651,515,919,1521,074,464,000769,945,0001,213,239,0001,801,184,0001,567,826,0001,542,551,0002,030,543,0002,439,438,0000
Dividend
Jul 08, 20250.42886 HKD/sh
Earnings
Aug 27, 2025

Profile

The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.
URL
http://www.tul.com.cn/
IPO date
Jun 15, 2007
Employees
14,000
Domiciled in
HK
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
13,758,937
0.14%
13,739,879
21.22%
11,334,262
16.81%
Cost of revenue
10,863,898
10,545,948
9,324,659
Unusual Expense (Income)
NOPBT
2,895,039
3,193,931
2,009,603
NOPBT Margin
21.04%
23.25%
17.73%
Operating Taxes
631,077
643,303
425,743
Tax Rate
21.80%
20.14%
21.19%
NOPAT
2,263,962
2,550,628
1,583,860
Net income
2,659,704
-1.54%
2,701,350
70.85%
1,581,094
60.01%
Dividends
(581,448)
(272,636)
Dividend yield
4.56%
3.06%
Proceeds from repurchase of equity
(1,880)
BB yield
0.02%
Debt
Debt current
835,165
200,362
1,363,102
Long-term debt
2,338,014
1,310,153
1,103,429
Deferred revenue
43,413
Other long-term liabilities
304,697
339,508
(237,482)
Net debt
(3,163,774)
(2,759,278)
(2,284,201)
Cash flow
Cash from operating activities
2,439,438
2,030,543
CAPEX
(1,274,484)
(779,548)
Cash from investing activities
(1,556,950)
(594,919)
Cash from financing activities
(1,362,678)
(24,166)
FCF
1,634,563
491,063
1,097,352
Balance
Cash
6,329,841
4,261,989
4,743,071
Long term investments
7,112
7,804
7,661
Excess cash
5,649,006
3,582,799
4,184,019
Stockholders' equity
14,435,240
7,312,960
6,886,949
Invested Capital
12,246,662
11,008,011
8,563,480
ROIC
19.47%
26.06%
18.96%
ROCE
16.18%
21.89%
15.53%
EV
Common stock shares outstanding
1,816,814
1,817,027
1,819,730
Price
12.36
76.32%
7.01
43.06%
4.90
12.39%
Market cap
22,455,821
76.30%
12,737,359
42.85%
8,916,677
11.14%
EV
19,339,004
9,990,921
6,633,821
EBITDA
2,895,039
3,759,579
2,544,379
EV/EBITDA
6.68
2.66
2.61
Interest
66,896
81,595
Interest/NOPBT
2.09%
4.06%